CD44 and colorectal cancer: This analysis showed that CD133, CD44, and SOX2 expression and ALDH activity were slightly increased in TCCM-treated colorectal cancer cells, whereas TCCM-DPA treated cancer cells exhibited a significant decrease in the expression/activity of these proteins (Figure 4F,G).